Price$44.36-1.47 (-3.20%)
01:30 PM07:45 PM
News · 26 weeks56-36%
2026-04-192026-10-11
Mix2990d
- SEC Filings10(34%)
- Other8(28%)
- Insider6(21%)
- Earnings3(10%)
- Analyst2(7%)
Latest news
25 items- SECSEC Form 8-K filed by Pulse Biosciences Inc8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- PRPulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid CenterCollaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical data Pulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to generate additional data on the use of nsPFA energy in benign thyroid nodule t
- PRPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Pulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on October 8, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to two new employees to purchase, in aggregate, up to 5,700 shares of Company common stock. The Company’s ind
- PRPulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026Preclinical evaluation of nPulse™ prototype endocardial catheters highlighted in session presentation Pulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the latest nPulse™ technology advancement will be featured during the 21st Annual International Ventricular Arrhythmias (VT) Symposium 2026, taking place October 9-10 in New York. A presentation at the Symposium will feature preclinical applications of two nPulse prototype endocardial catheters designed to demonstrate the potential for treatment of ventricular arrhythmias. Presentation | Pulse Field Abl
- SECSEC Form 8-K filed by Pulse Biosciences Inc8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- PRPulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment164 evaluable patients enrolled across 15 clinical sites Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites. "The compelling first-in-human dataset from the nPulse Cardiac Catheter System created significant investigator interest within the EP community across the United States," said Vivek Reddy, MD, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital, New York, and National Principal Investigator of the NANOPULSE-AF Study. "With
- ANALYSTBTIG Research initiated coverage on Pulse Biosciences with a new price targetBTIG Research initiated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $70.00
- SECSEC Form 424B5 filed by Pulse Biosciences Inc424B5 - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECPulse Biosciences Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECPulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- PRPulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid NodulesCompleted 100 patient enrollment across three U.S. sites; first patient enrolled completed 12-month follow-up Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules (BTNs). The first patient enrolled in the study completed the final 12-month follow-up visit in August at Sarasota Memorial Health Care System in Sarasota, Florida, under the supervision of Ralph P. Tufano, MD, MBA, FACS. And the 100th
- PRPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on September 2, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to two new employees to purchase, in aggregate, up to 2,200 shares of Company common stock. The Company’s independent Compe
- INSIDERChief Operating Officer Teplitsky Liane Rae bought $99,971 worth of shares (2,025 units at $49.37), increasing direct ownership by 98% to 4,095 units (SEC Form 4)4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- INSIDERChief Operating Officer Teplitsky Liane Rae bought $99,965 worth of shares (2,070 units at $48.29) (SEC Form 4)4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Teplitsky Liane Rae4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- INSIDERSEC Form 3 filed by new insider Teplitsky Liane Rae3 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Skinner Jon4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- INSIDERSEC Form 3 filed by new insider Skinner Jon3 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)
- PRPulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on August 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to 16,950 shares of Company common stock. The Company’s independent Comp
- ANALYSTNeedham initiated coverage on Pulse Biosciences with a new price targetNeedham initiated coverage of Pulse Biosciences with a rating of Buy and set a new price target of $58.00
- SECSEC Form 424B5 filed by Pulse Biosciences Inc424B5 - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECPulse Biosciences Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECSEC Form 10-Q filed by Pulse Biosciences Inc10-Q - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- SECPulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)
- PRPulse Biosciences Reports Business Updates and Second Quarter 2026 Financial ResultsPulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026. Recent Business Highlights Cash and cash equivalents totaled $101.6 million as of June 30, 2026. During Q2 the Company raised $46.8 million in net proceeds through an at-the-market (ATM) program, raising approximately $13 million from insiders and the remaining $33.8 million in net proceeds from outside investors. Subsequent to the close of Q2, the Company raised an additional $10.7 million in net proceeds through the ATM and $1.8 million
PLSE FAQ
7 questionsWhat does Pulse Biosciences Inc do?
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Where does PLSE stock trade?
Pulse Biosciences Inc (PLSE) is listed on NASDAQ.What sector and industry is PLSE in?
Pulse Biosciences Inc operates in the Health Care sector, Medical/Dental Instruments industry.When did Pulse Biosciences Inc go public?
Pulse Biosciences Inc (PLSE) completed its IPO in 2016.What are analysts saying about PLSE?
Pulse Biosciences Inc has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy on 2026-09-23. Recent price targets range from $2000.00 to $4300.00.What companies are similar to PLSE?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare PLSE side-by-side with any of them on Quantisnow.How can I track PLSE on Quantisnow?
Quantisnow aggregates Pulse Biosciences Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PLSE to receive live email and push alerts on every new disclosure.